E. Castelloe
Intercept Pharmaceuticals
6 Papers
85 Citations
E. Castelloe is an academic researcher from Intercept Pharmaceuticals. The author has contributed to research in topics: Obeticholic acid & Farnesoid X receptor. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Sunder Mudaliar,Robert R. Henry,Arun J. Sanyal,Linda Morrow,Hanns-Ulrich Marschall,Mark Kipnes,Luciano Adorini,Cathi Sciacca,Paul Clopton,E. Castelloe,Paul Dillon,Mark Pruzanski,David Shapiro +12 more
TL;DR: Administration of 25 or 50 mg OCA for 6 weeks was well tolerated, increased insulin sensitivity, and reduced markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.
918
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid
Gideon M. Hirschfield,Andrew Mason,Velimir A. Luketic,Velimir A. Luketic,Keith D. Lindor,Keith D. Lindor,Stuart C. Gordon,Marlyn J. Mayo,Kris V. Kowdley,Catherine Vincent,Henry C. Bodhenheimer,Henry C. Bodhenheimer,Albert Parés,Michael Trauner,Hanns-Ulrich Marschall,Luciano Adorini,Cathi Sciacca,Tessa Beecher-Jones,E. Castelloe,O. Bohm,David Shapiro +20 more
TL;DR: Daily doses of OCA significantly reduced levels of ALP, γ-glutamyl transpeptidase, and alanine aminotransferase, compared with placebo, in patients with primary biliary cirrhosis who had inadequate responses to ursodeoxycholic acid.
563
2 farnesoid-x receptor agonists: a new class of drugs for the treatment of pbc? an international study evaluating the addition of int-747 to ursodeoxycholic acid
Andrew Mason,Velimir A. Luketic,Keith D. Lindor,Gideon M. Hirschfield,Stuart C Gordon,Marlyn J. Mayo,Kris V. Kowdley,Albert Parés,M. Trauner,E. Castelloe,Cathi Sciacca,T.B. Jones,O. Bohm,David Shapiro +13 more
84
28 an international study evaluating the farnesoid x receptor agonist obeticholic acid as monotherapy in pbc
Kris V. Kowdley,D.E.J. Jones,Velimir A. Luketic,Roger W. Chapman,A.K. Burroughs,Gideon M. Hirschfield,Raoul Poupon,Christoph Schramm,Catherine Vincent,Christian Rust,Albert Parés,Andrew Mason,Cathi Sciacca,Tessa Beecher-Jones,O. Bohm,E. Castelloe,Mark Pruzanski,David Shapiro +17 more
68
410 24-week treatment with cts-1027 in combination with ribavirin reduces hcv-rna in treatment naive genotype-1 patients
Mario Chojkier,G.T. Everson,Andrew J. Muir,Bruce R. Bacon,Maribel Rodriguez-Torres,Michael B. Bennett,Michael Fried,S.C. Gordon,John B. Gross,David R. Nelson,Luis A. Balart,M. Jonas,Gyongyi Szabo,J. Bloomer,Arthur J. McCullough,L. Nyberg,Coleman Smith,O. Bohm,A.W. Fox,E. Castelloe,M. Huyghe,S. Mento,A. Spada +22 more
1